Literature DB >> 19656993

Analysis of the Fc gamma receptor-dependent component of neutralization measured by anthrax toxin neutralization assays.

Anita Verma1, Miriam M Ngundi, Bruce D Meade, Roberto De Pascalis, Karen L Elkins, Drusilla L Burns.   

Abstract

Anthrax toxin neutralization assays are used to measure functional antibody levels elicited by anthrax vaccines in both preclinical and clinical studies. In this study, we investigated the magnitude and molecular nature of Fc gamma (Fcgamma) receptor-dependent toxin neutralization observed in commonly used forms of the anthrax toxin neutralization assay. Significantly more Fcgamma receptor-dependent neutralization was observed in the J774A.1 cell-based assay than in the RAW 264.7 cell-based assay, a finding that could be due to the larger numbers of Fcgamma receptors that we found on J774A.1 cells by using flow cytometry. Thus, the extent to which Fcgamma receptor-dependent neutralization contributes to the total neutralization measured by the assay depends on the specific cell type utilized in the assay. Using Fcgamma receptor blocking monoclonal antibodies, we found that at least three murine Fcgamma receptor classes, IIB, III, and IV, can contribute to Fcgamma receptor-dependent neutralization. When antibodies elicited by immunization of rabbits with protective-antigen-based anthrax vaccines were analyzed, we found that the magnitude of Fcgamma receptor-dependent neutralization observed in the J774A.1 cell-based assay was dependent on the concentration of protective antigen utilized in the assay. Our results suggest that the characteristics of the antibodies analyzed in the assay (e.g., species of origin, isotype, and subclass), as well as the assay design (e.g., cell type and protective antigen concentration), could significantly influence the extent to which Fcgamma receptor-dependent neutralization contributes to the total neutralization measured by anthrax toxin neutralization assays. These findings should be considered when interpreting anthrax toxin neutralization assay output.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656993      PMCID: PMC2756837          DOI: 10.1128/CVI.00194-09

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  28 in total

1.  Optimized production and purification of Bacillus anthracis lethal factor.

Authors:  S Park; S H Leppla
Journal:  Protein Expr Purif       Date:  2000-04       Impact factor: 1.650

2.  Preparation of F(ab')2 fragments from mouse IgG of various subclasses.

Authors:  E Lamoyi; A Nisonoff
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

3.  New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2002-05-31

4.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

5.  Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax.

Authors:  Conrad P Quinn; Peter M Dull; Vera Semenova; Han Li; Shane Crotty; Thomas H Taylor; Evelene Steward-Clark; Karen L Stamey; Daniel S Schmidt; Kelly Wallace Stinson; Alison E Freeman; Cheryl M Elie; Sandra K Martin; Carolyn Greene; Rachael D Aubert; John Glidewell; Bradley A Perkins; Rafi Ahmed; David S Stephens
Journal:  J Infect Dis       Date:  2004-08-30       Impact factor: 5.226

6.  FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation.

Authors:  David A Mancardi; Bruno Iannascoli; Sylviane Hoos; Patrick England; Marc Daëron; Pierre Bruhns
Journal:  J Clin Invest       Date:  2008-10-23       Impact factor: 14.808

7.  Validation of the anthrax lethal toxin neutralization assay.

Authors:  Donna Hering; William Thompson; John Hewetson; Stephen Little; Sarah Norris; Judith Pace-Templeton
Journal:  Biologicals       Date:  2004-03       Impact factor: 1.856

8.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

9.  Characterization of a monoclonal antibody directed against mouse macrophage and lymphocyte Fc receptors.

Authors:  J C Unkeless
Journal:  J Exp Med       Date:  1979-09-19       Impact factor: 14.307

10.  Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.

Authors:  Nehal Mohamed; Juan Li; Claudia S Ferreira; Stephen F Little; Arthur M Friedlander; George L Spitalny; Leslie S Casey
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

View more
  17 in total

1.  Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.

Authors:  Rebecca A Brady; Anita Verma; Bruce D Meade; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-07-14

2.  Comparison of three anthrax toxin neutralization assays.

Authors:  Miriam M Ngundi; Bruce D Meade; Tsai-Lien Lin; Wei-Jen Tang; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2010-04-07

3.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

4.  In vivo veritas: the surprising roles of Fc receptors in immunity.

Authors:  Jeffrey Ravetch
Journal:  Nat Immunol       Date:  2010-03       Impact factor: 25.606

5.  Analysis of defined combinations of monoclonal antibodies in anthrax toxin neutralization assays and their synergistic action.

Authors:  Miriam M Ngundi; Bruce D Meade; Stephen F Little; Conrad P Quinn; Cindi R Corbett; Rebecca A Brady; Drusilla L Burns
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

6.  Contribution of Fc fragment of monoclonal antibodies to tetanus toxin neutralization.

Authors:  Somayeh Ghotloo; Mohammad Mehdi Amiri; Jalal Khoshnoodi; Ebrahim Abbasi; Mahmood Jeddi-Tehrani; Forough Golsaz-Shirazi; Fazel Shokri
Journal:  Neurotox Res       Date:  2019-11-13       Impact factor: 3.911

7.  Deglycosylation of mAb by EndoS for improved molecular imaging.

Authors:  Peng Gao; Kenneth L Pinkston; Nathaniel Wilganowski; Holly Robinson; Ali Azhdarinia; Banghe Zhu; Eva M Sevick-Muraca; Barrett R Harvey
Journal:  Mol Imaging Biol       Date:  2015-04       Impact factor: 3.488

8.  ADAM17 cleaves CD16b (FcγRIIIb) in human neutrophils.

Authors:  Yue Wang; Jianming Wu; Robert Newton; Nooshin S Bahaie; Chunmei Long; Bruce Walcheck
Journal:  Biochim Biophys Acta       Date:  2012-12-08

9.  Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia.

Authors:  L Hua; J J Hilliard; Y Shi; C Tkaczyk; L I Cheng; X Yu; V Datta; S Ren; H Feng; R Zinsou; A Keller; T O'Day; Q Du; L Cheng; M Damschroder; G Robbie; J Suzich; C K Stover; B R Sellman
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

10.  Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments.

Authors:  Anastasiya Yermakova; Nicholas J Mantis
Journal:  Toxicon       Date:  2013-04-17       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.